Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants

SARS-CoV-2 poses an unprecedented threat to the world as the causative agent of the COVID-19 pandemic. Among a handful of therapeutics developed for the prevention and treatment of SARS-CoV-2 infection, ensitrelvir is the first noncovalent and nonpeptide oral inhibitor targeting the main protease (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Mengmeng, Zeng, Xudong, Duan, Yinkai, Yang, Zinan, Ma, Yuanyuan, Yang, Haitao, Yang, Xiuna, Liu, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322880/
https://www.ncbi.nlm.nih.gov/pubmed/37407698
http://dx.doi.org/10.1038/s42003-023-05071-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322880/
https://www.ncbi.nlm.nih.gov/pubmed/37407698
http://dx.doi.org/10.1038/s42003-023-05071-y

Ejemplares similares